The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine.
The company said it has initiated manufacturing of the active pharmaceutical ingredient (API) and the finished product of the drug using technology from its unit, Pola Pharma Japan.
Sun Pharma shares gained after the announcement, and closed up 3.3% at 474.25 rupees. Shares in Indian drugmakers have been on a tear this year, with the Nifty pharma index rising 21.5% so far.
https://www.reuters.com/article/us-health-coronavirus-sun-pharma/sun-pharma-to-test-pancreatitis-drug-in-covid-19-patients-in-india-idUSKBN2351AJ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.